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Precocious puberty is the development of secondary sexual char-
acteristics before the age of 8 years in girls (onset of thelarche)
and 9 years in boys (increase in testicular volume).1 Clinical and
biochemical assessment is directed at determining whether the
underlying process is gonadotrophin-dependent (central preco-
cious puberty (CPP)), associated with activation of the
hypothalamic-pituitary-gonadal (HPG) axis, or gonadotrophin-
independent (peripheral precocious puberty (PPP)) which is char-
acterised by elevated sex steroids but low gonadotrophin levels.
Although less common, the clinical consequences of PPP are no
less severe, and the diagnosis is crucial to ensure appropriate
management.2 The inherited forms of PPP include non-salt wast-
ing forms of Congenital Adrenal Hyperplasia, McCune-Albright
Syndrome (MAS) and familial male-limited precocious puberty.
Acquired PPP occurs secondary to exposure to endogenous (eg.
adrenal, gonadal or other malignancies) or exogenous sex ster-
oids.3 We present cases of siblings with virilisation from transder-
mal exposure to ‘bioidentical’ testosterone (bioT).
Case Reports
The siblings were a 5-year 9-month old boy (Patient 1, PT1) and his
4-year 6-month old sister (Patient 2, PT2). PT1 was referred for
concerns regarding increasing aggression and onset of masturbatory
behaviour. There had also been gradual phallic enlargement, devel-
opment of pubic and axillary hair and acceleration in growth
velocity over a period of 18 months. There were no associated
headaches, visual disturbances or abdominal, pelvic or scrotal/tes-
ticular pain. There was no family history of pubertal disorders.
Paternal pubertal timing was concordant with his peers. Maternal
menarche occurred at age 11 years and she did not report men-
strual irregularities or difﬁculties conceiving her two children.
The marriage was non-consanguineous. The father was a keen
cyclist. His libido was described as ‘out of control’ by his wife. On
examination, PT1 had no cutaneous stigmata or increased pig-
mentation, his blood pressure was within the age-speciﬁc range,
there were no abdominal or pelvic masses, and his neurological
examination was unremarkable. His height was >97th percentile,
weight >97th percentile. He had Tanner stage 3 genital
(G3) development with increased scrotal size and rugosity, and a
stretch penile length of 8.5 cm (>90th percentile) (Fig. 1). He had
Tanner stage 2–3 pubic hair (PH2–3), and some early axillary hair
(A1–2). His testicular volumes were pre-pubertal (2 mL on the
left and 2–3 mL on the right). During the consultation, the par-
ents revealed that PT2 had also developed emotional lability and
onset of pubic hair development. Her examination revealed Tan-
ner stage 2 pubic hair (PH2), no axillary hair (A1) and obvious
clitoral enlargement. There was no evidence of thelarche (breast
Tanner stage 1, B1). Both PT1 and PT2 had signiﬁcant advance-
ment in skeletal maturity on bone age assessment. The clinical,
biochemical and radiological features of the two cases are sum-
marised in Table 1. Both children had elevated testosterone con-
centrations (PT1 2.2 nmol/L and PT2 4.2 nmol/L), pre-pubertal
gonadotrophin levels, negative tumour markers (hCG and AFP)
and normal baseline 17-hydroxyprogesterone (17-OHP) levels.
A diagnosis of virilisation secondary to exogenous testosterone
exposure was made. The father subsequently admitted to using
transdermal 15% liposomal testosterone cream, a bioT prepared
by a local compounding service specialising in complementary
medicines, for the past 2.5 years (Fig. 2). This had been pre-
scribed by his general practitioner, unbeknownst to his wife, for
decreased energy levels and declining libido. There had been no
biochemical assessment for andropause prior to commencement
of the bioT. He denied having been warned about the importance
of washing his hands after applying the bioT, and avoiding
skin-to-skin contact with others – either by his general practi-
tioner or the compounding service. His testosterone concen-
tration measured in the late afternoon, approximately 3 h
before the nightly application of bioT cream, was 45.9 nmol/L
(11.0–40.0). Owing to the uncertainty around the exact com-
position of the bioT, and the low-normal morning cortisol
concentrations in PT1 (range 100–113 nmol/L), a short
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Fig. 1 Anthropometry for Patient 1. The patient’s height had increased from the 90th percentile to above the 97th percentile in the past 18 months. The
bone age (X) was advanced with a skeletal maturity (Greulich and Pyle) of 7 years 6 months at a chronological age of 5 years 9 months. The stretch penile
length is 8.5 cm (>90th percentile for age). BSA, body surface area; MPH, mid-parental height.
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synacthen test was performed which excluded cortisol deﬁ-
ciency (cortisol concentration at baseline 94 nmol/L with peak
696 nmol/L at 1 h).
The parents were advised of the importance of ensuring no fur-
ther exposure to the bioT cream. Over the subsequent months,
both children experienced a normalisation of their behaviour and
measured testosterone concentrations were within the pre-
pubertal ranges.
Discussion
These cases illustrate the importance of an understanding of the
normal physiology of pubertal development, and the associated
Table 1 Clinical, biochemical and radiological characteristics of patients with virilisation secondary to exogenous testosterone exposure
Patient 1 Patient 2
Clinical characteristics
Age 5 years 9 months 4 years 6 months
Gender Male Female
Presenting symptoms and signs Increased aggression, erections and masturbatory behaviour Emotional lability
Onset of pubic and axillary hair, phallic enlargement Onset of pubic hair, clitoral enlargement
Increased growth velocity Increased growth velocity
Duration of symptoms 18 months 18 months
Tanner stage G3PH2-3A1-2 PH2A1B1
Testicular volume – right 2 mL, left 2–3 mL Clitoromegaly
Stretched penile length 8.5 cm
Height 126.1 cm (>97th percentile) 115.1 cm (>97th percentile)
Mid-parental height – 184 cm (75–90th percentile) Mid-parental height – 171 cm (90th percentile)
Weight 29.1 kg (>97th percentile) 23.5 kg (97th percentile)
Body mass index 18.3 kg/m2 (90–95th percentile) 18.9 kg/m2 (>97th percentile)
Biochemical and radiological investigations
Luteinising hormone 0.1 IU/L (<2) <0.7 IU/L (<7.0)
Follicle-stimulating hormone 0.6 IU/L (<3) 0.2 IU/L (<5.0)
Testosterone 2.2 nmol/L (<0.7) 4.2 nmol/L (<0.5)
Oestradiol — <30 pmol/L (<100)
DHEAS 0.2 μmol/L (0.1–2.3) <0.5 μmol/L (<1.0)
Androstenedione — 0.1 nmol/L (0.1–0.7)
17-hydroxyprogesterone 0.4 nmol/L (0.3–4.0) 0.1 nmol/L (0.1–3.2)
Baseline morning cortisol Range: 100–113 nmol/L —
ACTH 13 ng/L (10–50) —
Tumour makers (hCG and AFP) Negative Negative
Bone age (Greulich and Pyle) 7 years 6 months 6 years 6 months
Anthropometry using Australasian Paediatric Endocrine Group (APEG) growth charts. See text for Tanner stage details. All biochemical measurements
are via immunoassay-based methods. ACTH, adrenocorticotropic hormone; AFP, alpha-fetoprotein; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-
stimulating hormone; hCG, human chorionic gonadotropin; LH, luteinising hormone.
Fig. 2 Custom-compounded ‘bioidentical’
testosterone (Testosterone 15% Liposomal
cream) which was the source of exoge-
nous exposure resulting in severe virilisa-
tion in the patients.
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biochemical changes. The absence of testicular enlargement in PT1
and thelarche in PT2, in combination with low gonadotrophins, con-
ﬁrmed a gonadotrophin-independent process. The normal baseline
17-OHP concentrations in both children did not support the diagno-
sis of Congenital Adrenal Hyperplasia secondary to 21-hydroxylase
deﬁciency, the most common form of the inherited disorders of
adrenal steroidogenesis. Despite the low Luteinising hormone
(LH) level, the absence of testicular enlargement and the devel-
opment of virilisation in PT2, was inconsistent with familial
male-limited precocious puberty as females are unaffected.
The annual expenditure for testosterone products in Australia
has increased from $1.4 million to $12.7 million between 1992
and 2010.4 This dramatic rise has been attributed to the extension
of prescribing beyond the indication of replacement therapy in
pathological hypogonadism secondary to pituitary or testicular
disease, to ‘treatment’ in older men with low circulating levels of
testosterone. This phenomenon has precipitated a change in the
Pharmaceutical Beneﬁts Scheme criteria for testosterone prescrib-
ing to include the requirement for initiation of treatment only by
a specialist, or in consultation with a specialist.5
Testosterone therapy is commonly delivered via the transder-
mal route using patches, gels or solutions. Transdermal adminis-
tration has a number of advantages over the parenteral (deep
subcutaneous or intramuscular) and oral routes including compa-
rable or better bioavailability, better titratability, ease of adminis-
tration and improved compliance.6 In the case of gels and
solutions, one of the distinct disadvantages is the potential for
inadvertent transfer of testosterone to other individuals following
skin-to-skin contact.
The proliferation of compounding services is a reﬂection of the
increasing demand for alternative preparations of commonly pre-
scribed medications. Liquid preparations are often sought when swal-
lowing tablets or capsules is difﬁcult. However, there are well-
described examples of incomplete bioequivalence between oral and
liquid preparations including thyroxine7 and hydrocortisone.8 ‘Bioi-
dentical’ hormones are custom-compounded preparations which are
purported to contain hormones with the same molecular structure as
the endogenous hormones. In some cases, these are multi-hormone
preparations with the speciﬁc aim of replicating the physiological hor-
monal milieu. They are promoted as ‘natural’ but, in reality, may be
derived from plant, animal or synthetic sources.9 With regards to the
manufacturing of medicines, a licence from the therapeutic goods
administration (TGA) is not required when production occurs in
a pharmacy, which is open to the public, or on the premises of a
private hospital. In addition, the compounded medicines are
exempt from registration on the Australian Register of Therapeu-
tic Goods provided they are extemporaneously prepared for a
speciﬁc therapeutic application to a particular person. They must,
however, meet the quality standards set out in the Therapeutic
Goods Act 1989.10 Pharmacists are required to comply with the
‘Guidelines on Compounding of Medicines’ by the Pharmacy
Board.11 This document provides guidance on aspects of the
manufacturing process including facilities, working environments
and equipment, documentation, labelling, reporting of adverse
events and formulation considerations. These formulation consid-
erations include the modiﬁcation of commercially available pro-
ducts as well as the preparation of ‘formulations for which
precedents do not exist’ including hormones. Pharmacists are also
expected to comply with all relevant professional practice
standards and guidelines, and guidance published by the Phar-
macy Board. Compliance is monitored by the state/territory phar-
macy premises regulatory authority or responsible body through
audits or inspections.10 The TGA is in the ﬁnal stages of consulta-
tion about possible changes to the regulation of compounded
medicines. The long-term exposure of these children to bioT has
resulted in virilisation, which will not resolve completely despite
discontinuation of exposure. The acceleration in skeletal matura-
tion is likely to result in some degree of compromised ﬁnal adult
height. Chronic exposure to androgens can also prime the HPG
axis resulting in CPP. This can result in further compromise to
ﬁnal adult height and close ongoing monitoring for CPP is impor-
tant in these children. Consideration must also be given to the
unknown psychosocial effects of pre-pubertal exposure to sex
steroids. Within the context of a thriving and unregulated com-
plementary medicine industry, and the wide availability and use
of custom-compounded ‘bioidentical’ hormones, exposure to
exogenous sex steroids should be considered in the diagnosis of
gonadotrophin-independent precocious puberty.
Multiple Choice Questions




c) Transdermal exposure to exogenous testosterone
d) Luteinizing hormone/Choriogonadotropin receptor
heterozygous gain-of-function mutation
e) 3β-hydroxysteroid dehydrogenase deﬁciency
Answer: d. Female carriers of activating mutations of the LH
receptor are completely asymptomatic, due to the requirement
for both LH and FSH activity for ovarian steroidogenesis. 21-
hydroxylase and 3β-hydroxysteroid dehydrogenase deﬁciency are
inherited enzymatic defects in adrenal steroidogenesis resulting
in increased activity in the androgen production pathway.
2 Patients with McCune-Albright Syndrome commonly present
with all of the following except
a) Breast development
b) Painless vaginal bleeding
c) Virilisation
d) Fibrous dysplasia of bone
e) Café au lait skin pigmentation
Answer: c. MAS is characterised by a triad of precocious puberty,
café au lait skin pigmentation and ﬁbrous dysplasia of bone. The
constitutive activation of G-protein signalling in the ovary causes
autonomous function and development of large, unilateral,
oestrogen-producing ovarian cysts. This oestrogen promotes breast
development and endometrial thickening. The rupture of these
cysts and subsequent oestrogen withdrawal results in vaginal bleed-
ing. Early central activation of the HPG axis can occur due to long-
term exposure and subsequent withdrawal of oestrogen but abnor-
mal virilisation is not commonly seen at presentation.
3 The ﬁrst-line investigation of precocious puberty should
include all of the following except
a) Urinary steroid proﬁle
b) Sex steroids (testosterone or oestradiol)
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Answer: a. Urinary steroid proﬁles are useful for the diagnosis of dis-
orders of steroidogenesis but are not sufﬁciently sensitive to detect
hormonal changes seen in early puberty. LH, FSH and sex steroid
measurements are important for determining whether the process is
central or peripheral. Bone age assists in estimation of duration of the
precocious puberty, and prediction of ﬁnal adult height.
References
1 Nathan BM, Palmert MR. Regulation and disorders of pubertal timing.
Endocrinol. Metab. Clin. North Am. 2005; 34: 617–41, ix.
2 Eugster EA. Peripheral precocious puberty: Causes and current man-
agement. Horm. Res. 2009; 71 (Suppl. 1): 64–7.
3 Martinez-Pajares JD, Diaz-Morales O, Ramos-Diaz JC, Gomez-
Fernandez E. Peripheral precocious puberty due to inadvertent expo-
sure to testosterone: Case report and review of the literature.
J. Pediatr. Endocrinol. Metab. 2012; 25: 1007–12.
4 Handelsman DJ. Pharmacoepidemiology of testosterone prescribing
in Australia, 1992–2010. Med. J. Aust. 2012; 196: 642–5.
5 Yeap BB, Grossmann M, McLachlan RI et al. Endocrine Society of
Australia position statement on male hypogonadism (part 1): Assess-
ment and indications for testosterone therapy. Med. J. Aust. 2016;
205: 173–8.
6 Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur.
J. Pharm. Biopharm. 2015; 92: 42–8.
7 Cassio A, Monti S, Rizzello A et al. Comparison between liquid and
tablet formulations of levothyroxine in the initial treatment of congen-
ital hypothyroidism. J. Pediatr. 2013; 162: 1264–9, 1269.e1–2.
8 Spinks JJ, Ahmed ML, Ryan FJ, Edge JA. Dangers of liquid drug pre-
parations. J. Pediatr. Endocrinol. Metab. 2007; 20: 1249.
9 Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M,
Pinkerton JV. Compounded bioidentical hormones in endocrinology
practice: An endocrine society scientiﬁc statement. J. Clin. Endocrinol.
Metab. 2016; 101: 1318–43.
10 Pharmacy Board of Australia. Background on the Regulation of Com-
pounding by Pharmacists. Canberra: Australian Health Practitioner
Regulation Agency; 2016. Available from: http://www.pharmacyboard.
gov.au/Codes-Guidelines.aspx [accessed 1 November 2016].
11 Pharmacy Board of Australia. Guidelines on Compounding of Medicines.
Canberra: Australian Health Practitioner Regulation Agency; 2016.
Available from: http://www.pharmacyboard.gov.au/Codes-Guidelines.
aspx [accessed 1 November 2016].
Cats by Kiara Fink (age 8) from Operation Art 2016
Journal of Paediatrics and Child Health 53 (2017) 301–305
© 2017 Paediatrics and Child Health Division (The Royal Australasian College of Physicians)
305
T Huynh and C Stewart Peripheral precocious puberty
